Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-03-13

Clinical Trial Update: Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety and efficacy of psilocybin for body dysmorphic disorder has completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Psilocybin (psilocybin)

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Body Dysmorphic Disorders | Phase 2 | Status: COMPLETED | Results posted: 2023-03-13